Epoetin beta

19 Items
Dosage form
Brand & Manufacturer
Package Size
$214.00
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Eralfon - a treatment for anemia.
Epoetin alfa, a glycoprotein that specifically stimulates erythropoiesis, activates mitosis and maturation of erythrocytes from erythrocyte progenitor cells.
In its composition, biological and immunological properties of epoetin alfa is identical to the natural human erythropoietin.

The introduction of epoetin alfa leads to an increase in hemoglobin and hematocrit, improving the blood supply to the tissues and heart function. The most pronounced effect of the use of epoetin alfa is observed with anemia caused by chronic renal failure.

Indications

- anemia in patients with chronic renal failure, including those on hemodialysis;

- prevention and treatment of anemia in patients with solid tumors, anemia in which was the result of antitumor therapy;

- prevention and treatment of anemia in patients infected with human immunodeficiency virus (HIV), caused by the use of zidovudine, when the level of endogenous erythropoietin is less than 500 IU / ml;

- prevention and treatment of anemia in patients with myeloma, low-grade non-Hodgkins lymphomas, chronic lymphatic leukemia, in patients with rheumatoid arthritis;

- treatment and prevention of anemia in premature babies born with low body weight up to 1.5 kg;

- as part of a pre-posit program before extensive surgery in patients with a hematocrit of 33-39%, to facilitate the collection of autologous blood and reduce the risk associated with the use of allogeneic blood transfusions, if the expected need for transfused blood exceeds the amount that can be obtained by autologous collection without the use of epoetin alfa;

- before carrying out an extensive operation with the expected blood loss of 900-1800 ml in adult patients without anemia or with mild and moderate anemia (hemoglobin level 100-130 g / l) to reduce the need for allogeneic hemotransfusions and facilitate the recovery of erythropoiesis.

Composition

1 ampoule (1 ml) contains Epoetin alfa (REPOETIN-SP - human recombinant erythropoietin) as active substance 10,000 IU.

Excipients: albumin solution, sodium citrate pentasesquihydrate or sodium citrate dihydrate, sodium chloride, citric acid monohydrate, water for injection

No customer reviews for the moment.

Write your review

Write your review

Epoetin beta
  • Brand name: Recormon
  • Active ingredient: Epoetin beta
  • Manufacturer: Berry Plus

Studies and clinical trials of Epoetin beta (Click to expand)

  1. Kinetics of reticulocyte maturity fractions and indices and iron status during therapy with epoetin beta (recombinant human erythropoietin) in cardiac surgery patients
  2. Epoetin beta therapy in patients with solid tumours
  3. Preoperative treatment of anemic women with epoetin beta
  4. Epoetin alpha and beta in their erythropoetin isoform compositions and biological properties
  5. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production
  6. Epoetin alpha, epoetin beta and darbepoetin alfa: Two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis
  7. Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography–tandem mass spectrometry
  8. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy—results of a randomized trial
  9. Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study
  10. Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery
  11. Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment
  12. Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy
  13. Is once-weekly epoetin beta ‘highly effective’ in treating anaemia in patients with lymphoproliferative malignancy?
  14. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production
  15. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study
  16. Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting
  17. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy
  18. Effective treatment of anemia in pediatric kidney transplant recipients with methoxy polyethylene glycol-epoetin beta
  19. Anaemia in patients with chronic kidney disease: Management with epoetin beta in primary care setting in New Zealand
  20. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer
  21. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta
  22. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study
  23. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

Customers who bought this product also bought:

8 other products in the same category:

arrow_upward